Carmignac Gestion Has $148.67 Million Stock Holdings in Lantheus Holdings, Inc. $LNTH

Carmignac Gestion lifted its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 0.9% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,340,100 shares of the medical equipment provider’s stock after purchasing an additional 12,100 shares during the period. Lantheus comprises 1.9% of Carmignac Gestion’s investment portfolio, making the stock its 16th largest holding. Carmignac Gestion’s holdings in Lantheus were worth $148,671,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in LNTH. EverSource Wealth Advisors LLC increased its position in Lantheus by 190.2% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,065 shares of the medical equipment provider’s stock valued at $87,000 after acquiring an additional 698 shares during the period. First Trust Advisors LP lifted its holdings in shares of Lantheus by 37.4% during the second quarter. First Trust Advisors LP now owns 69,805 shares of the medical equipment provider’s stock worth $5,714,000 after purchasing an additional 19,008 shares during the period. Baird Financial Group Inc. lifted its holdings in shares of Lantheus by 22.6% during the second quarter. Baird Financial Group Inc. now owns 2,715 shares of the medical equipment provider’s stock worth $222,000 after purchasing an additional 500 shares during the period. Daiwa Securities Group Inc. grew its stake in shares of Lantheus by 88.1% in the second quarter. Daiwa Securities Group Inc. now owns 3,396 shares of the medical equipment provider’s stock worth $278,000 after purchasing an additional 1,591 shares during the last quarter. Finally, Osterweis Capital Management Inc. bought a new stake in shares of Lantheus in the second quarter worth $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on LNTH. Weiss Ratings raised Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research report on Thursday, August 27th. Truist Financial cut Lantheus from a “buy” rating to a “hold” rating and decreased their price target for the company from $125.00 to $102.50 in a research note on Monday, August 3rd. William Blair set a $102.50 price objective on Lantheus in a research report on Monday, August 3rd. Mizuho cut their price objective on Lantheus from $120.00 to $115.00 and set an “outperform” rating on the stock in a research note on Wednesday, July 29th. Finally, B. Riley Financial lowered Lantheus from a “buy” rating to a “hold” rating in a research note on Monday, August 17th. Four analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and an average price target of $108.11.

Lantheus Trading Down 0.5%

LNTH stock traded down $0.53 during midday trading on Tuesday, hitting $100.44. The stock had a trading volume of 1,088,870 shares, compared to its average volume of 1,099,459. The firm has a market cap of $6.56 billion, a P/E ratio of 24.26 and a beta of -0.03. The company has a current ratio of 3.06, a quick ratio of 2.89 and a debt-to-equity ratio of 0.43. Lantheus Holdings, Inc. has a 1-year low of $49.67 and a 1-year high of $111.86. The business has a fifty day moving average price of $102.94 and a two-hundred day moving average price of $93.12.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, beating analysts’ consensus estimates of $1.30 by $0.25. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The business had revenue of $388.18 million for the quarter, compared to analysts’ expectations of $363.23 million. During the same quarter in the prior year, the firm posted $1.57 earnings per share. The business’s quarterly revenue was up 2.7% compared to the same quarter last year. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 4.5 earnings per share for the current fiscal year.

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.